Success Stories: EB1B Approval for a Medicinal Chemistry Research Associate in 3 days
On May 23rd, 2013, we received another EB-1B (Outstanding Professor or Researcher) Approval for a Research Associate in the Field of Medicinal Chemistry Working for the a Large State University (Approval Notice)
General Field: Medicinal Chemistry
Petitioner: Large State University
Position at the Time of Case Filing: Research Associate
National Origin: India
Service Center: Texas Service Center (TSC)
State Residing at the Time of Filing: Oklahoma
Approval Notice Date: May 23, 2013
Processing Time: 3 days
Case Summary:
Recently, Chen Immigration Law Associates had the pleasure of working with a research associate from India with a specialization in medicinal chemistry. The beneficiary’s work focused in the highly specialized areas of drug discovery, synthesizing new drug scaffolds, and developing methods fro the sequencing of complex molecular architectures of known chemical entities. The petitioner is a large, public, Oklahoma university. The university acted as the sponsoring employer in this case, proving their ability to pay the beneficiary’s salary and their proven track record of achievement in the field of biomedical engineering. The beneficiary’s research has resulted in one United States patent, 18 peer-reviewed scientific articles published in leading journals, and 15 conference presentations. His publications have been cited at least 39 times by researchers around the world, demonstrating the international recognition for his work. Additionally, we submitted several strong recommendation letters from experts and researchers in the shared field confirming the beneficiary’s significant contributions and international recognition as an outstanding researcher in the field of endeavor. His expertise can also be seen in a quote by an independent recommender, “[The beneficiary’s] high level of skill in this field is apparent and necessary. The work in my laboratory and the chemistry field at large would be negatively impacted if his research were forced to end. His work is crucial for addressing health issues of the nation.” The beneficiary’s petition was swiftly approved in just three days.